Cas:9001-19-8 α-Amylase manufacturer & supplier

We serve Chemical Name:α-Amylase CAS:9001-19-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

α-Amylase

Chemical Name:α-Amylase
CAS.NO:9001-19-8
Synonyms:2-[(3-Aminopropanoyl)amino]-3-(1H-imidazol-4-yl)propanoic acid;TAKA-DIASTASE;IUB: 3.2.1.1;Histidine, β-alanyl-;alpha-amylasefromaspergillusoryzae;N-(3-Aminopropanoyl)histidine;TAKA-AMYLASE A;Amylase,.alpha.-,Aspergillusoryzae;b-Alanylhistidine;β-Alanylhistidine;Amylase,.alpha.-Aspergillusoryzae;carnosine;CLARASE;DIASTASE TAKAMINE
Molecular Formula:C9H14N4O3
Molecular Weight:226.232
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:656.2±55.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.591
PSA:
Exact Mass:226.106583
LogP:-2.17

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like 2-[(3-Aminopropanoyl)amino]-3-(1H-imidazol-4-yl)propanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DIASTASE TAKAMINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,alpha-amylasefromaspergillusoryzae Use and application,β-Alanylhistidine technical grade,usp/ep/jp grade.


Related News: GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� α-Amylase manufacturer This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. α-Amylase supplier FT was defined as any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost. α-Amylase vendor Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. α-Amylase factory This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement.